Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) announced that on November 24, 2025 its Compensation Committee granted stock options to purchase an aggregate of 151,250 shares of common stock to 12 newly hired employees under the company’s 2025 New Hire Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).

Per the awards, 25% of each grantee’s options vest on the first anniversary of employment, with the remainder vesting ratably each quarter over the following three years. The company provided these details to comply with Nasdaq disclosure requirements.

NEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on November 24, 2025, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 151,250 shares of the Company’s common stock to 12 newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4).

Twenty-five percent of the stock options granted to each new employee will vest on the first anniversary of the date such employee commenced employment with the Company, with the remainder vesting ratably each quarter over the following three-year period.

Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com

FAQ

How many shares did Orchestra BioMed (OBIO) grant on November 24, 2025?

Orchestra BioMed granted stock options to purchase an aggregate of 151,250 shares on November 24, 2025.

How many employees received inducement option grants from OBIO on November 24, 2025?

12 newly hired employees received option grants under the 2025 New Hire Inducement Plan.

What is the vesting schedule for OBIO inducement options granted November 24, 2025?

25% vests on the first employment anniversary, then the remainder vests ratably each quarter over the next three years.

Why did Orchestra BioMed (OBIO) disclose these stock option grants?

The disclosure was made to comply with Nasdaq Listing Rule 5635(c)(4), which covers inducement awards for newly hired employees.

Do the November 24, 2025 OBIO option grants immediately dilute existing shareholders?

The grants are options to purchase shares and do not represent immediate share issuance; dilution would occur only if and when the options are exercised.